Professor Graeme Milligan

  • Gardiner Chair of Biochemistry (Institute of Molecular Cell and Systems Biology)
  • Dean of Research (MVLS College Senior Management)

telephone: 01413305557
email: graeme.milligan@glasgow.ac.uk

Biography

Graeme Milligan Ph.D., FRSE, FMEd Sci, FBPharmacolS

Education/Training
1976-1979: University of Birmingham: Graduated with B.Sc. (Hons. 1st class) Biochemistry.
1979-1982: University of Nottingham: Graduated with Ph.D.
1982-1985: Fogarty International Visiting Fellow, National Institute of Mental Health Bethesda, MD. U.S.A.

Current Positions
1994-present: Professor of Molecular Pharmacology, University of Glasgow, Glasgow, Scotland, U.K.
2010-present: Dean of Research, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, U.K.
2012-present: Gardiner Professor of Biochemistry, University of Glasgow, Glasgow, Scotland, U.K.
I was elected to the Fellowship of the Royal Society of Edinburgh in 1998 and to the Fellowship of the Academy of Medical Sciences in 2016.

Awards
The ‘Poulsson’ Medal for Pharmacology: Norwegian Society of Pharmacology and Toxicology. 1998.
The Ariens Medal: Dutch Pharmacological Society. 2006
The JR Vane Medal for Pharmacology: British Pharmacological Society. 2016

My main research group centres on the function, structure and regulation of G protein-coupled receptors (GPCRs) and their interacting proteins. I have published more than 500 peer-reviewed articles on these topics. My research has been cited more than 22,000 times and I am a Thompson Reuters 2014 Highly Cited Researcher.

‌In 2015 I co-founded Caldan Therapeutics. Caldan Therapeutics discovers novel therapeutics for metabolic diseases including Type 2 Diabetes and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases.

I was a finalist in the Biosciences and Biotechnology Research Council ‘Innovator of the Year 2016’ competition.

Research interests

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Defining the functional modes of action, and therapeutic potential of targeting, the free fatty acid receptor FFA4 in the lung
    Medical Research Council
    2018 - 2020
     
  • Defining signal selection from the free fatty acid receptor FFA4; implications for
    Biotechnology and Biological Sciences Research Council
    2017 - 2021
     
  • Defining the functional roles of the enigmatic G protein coupled receptor GPR35
    Biotechnology and Biological Sciences Research Council
    2017 - 2021
     
  • Functional analysis of insect neuropeptide G protein-coupled receptors
    Biotechnology and Biological Sciences Research Council
    2017 - 2020
     
  • GRACE II: new horizons and consolidation
    Medical Research Council
    2017 - 2018
     
  • Glasgow Research Accelerator Collaborative Exchange (GRACE) - translating research excellence to realise solutions.
    Medical Research Council
    2015 - 2017
     
  • Designer Receptor Exclusively Activated by Designer Drug' to define the role of short chain fatty acids in metabolic disease and inflammation (Fatty acid DREADD)
    Biotechnology and Biological Sciences Research Council
    2014 - 2014
     
  • The organisational structure of class A GPCRs: Implications for pharmacology, function and therapeutic regulation
    Medical Research Council
    2014 - 2019
     
  • Production of pan-species antagonists and validation of GPR43 as an ant-inflammatory and anti-diabetic target
    Scottish Universities Life Sciences Alliance
    2014 - 2015
     
  • Angiotensin-(1-7) and angiotensin-(1-9): assessment as therapeutic targets in acute vascular injury and remodelling.
    Medical Research Council
    2014 - 2017
     
  • BHF centre of excellence
    British Heart Foundation
    2014 - 2019
     
  • Red blood cell programme
    Scottish Enterprise
    2013 - 2016
     
  • GPR120: a G protein-coupled receptor with the potential to regulate insulin secretion and inflammation
    Biotechnology and Biological Sciences Research Council
    2013 - 2017
     
  • FFARMED - The molecular effects of food on metabolic diseases through nutrient sensing free fatty acid receptors
    Danish Agency for Science, Technology and Innovation
    2012 - 2017
     
  • Identification of novel FFA1 and GPR120 ligands and their use in elucidating the pharmacology, function, and clinical utility of these receptors in the treatment of obesity and diabetes
    Canadian Institutes of Health Research
    2011 - 2014
     
  • Characterisation of T16, a novel stem cell survival compound (ISSF Catalyst Fund)
    Wellcome Trust
    2011 - 2014
     
  • Developing selective ligands for Free Fatty Acid Receptor 2 with novel pharmacological properties
    Wellcome Trust
    2010 - 2013
     
  • Dissecting the mechanism of action of the novel renin angiotensin hormone angiotensin1-9
    Medical Research Council
    2010 - 2013
     
  • The organisational structure of class A GPCRs: implications for function and drug design
    Medical Research Council
    2009 - 2014
     
  • Interrogation and manipulation of micro RNA during differentiation of human ES cells to cardiomyocyte and vascular lineages
    British Heart Foundation
    2009 - 2013
     
  • Molecular basis of the functional regulation of mu opioid receptors by co-expressed Gq/G11-coupled GPCRs
    Biotechnology and Biological Sciences Research Council
    2008 - 2011
     
  • Uncovering the pharmacology of the G-protein coupled reception GPR40
    Biotechnology and Biological Sciences Research Council
    2008 - 2011
     
  • Regulation of bone metabolism by cannabinoid receptors: mechanisms of action and implications for the treatment of bone disease
    Arthritis Research Campaign
    2008 - 2008
     
  • Exploring the selectivity and consequences of GPCR homo and hetero dimerisation/oligomerisation using receptors activated solely by ......
    Biotechnology and Biological Sciences Research Council
    2007 - 2010
     
  • The molecular basis of cannabinoid CB1 receptor regulation of the sensitivity of orexin-1 receptor signalling
    Biotechnology and Biological Sciences Research Council
    2005 - 2009
     
  • The existence and functional importance of interactions between opiod receptors and the CXCR1/2 chemokine receptors
    Wellcome Trust
    2005 - 2008
     
  • Protein interactions and compartmentalisation in cell signalling
    Medical Research Council
    2005 - 2008
     
  • The quaternary structure of G-protein coupled receptors - implications for function and drug design.
    Medical Research Council
    2004 - 2009
     
  • Mechanisms and basis of G protein-indepedent signal transduction by the orexin-1 receptor
    Wellcome Trust
    2004 - 2007
     
  • H1R Signalling and Immune Deviation in EAE
    National Institutes of Health
    2003 - 2005
     
  • Subcellular compartmentalisation analysis by confocal microscopy
    Biotechnology and Biological Sciences Research Council
    2003 - 2007
     
  • The interactions between G11 alpha and regulators of G protein signalling and the mechanisms of receptor dimerisation monitored by single..
    Wellcome Trust
    2003 - 2006
     
  • Post transitional modification and the function of regulator of G protien signalling
    Biotechnology and Biological Sciences Research Council
    2003 - 2006
     
  • The specificity and basis of GPRC hetero-oligomerisation
    Biotechnology and Biological Sciences Research Council
    2003 - 2006
     

Additional information

Editorial Board

  • 2015 - ongoing: Pharmacological Reviews
  • 2004 - ongoing: BMC Cell Biology
  • 1996 - 1999: British Journal of Pharmacology
  • 1995 - ongoing: Molecular Pharmacology
  • 1995 - 2002: Biochemical Journal
  • 1989 - 2002: Biochemical Pharmacology

Grant Advisory Board

  • 2010 - ongoing: Anchor Therapeutics - Member of Scientific Advisory Board (http://www.anchortx.com/)
  • 2007 - 2011: Heptares Therapeutics Limited - Member of Scientific Advisory Board. http://www.heptares.com/
  • 2006 - ongoing: Faculty of 1000 - Section Head 'Molecular Pharmacology'
  • 2005 - ongoing: IUPHAR - Member Nomenclature committee; GPCR dimer committee
  • 2005 - ongoing: Cara Therapeutics - Member of Scientific Advisory Board. http://www.caratherapeutics.com/
  • 2004 - ongoing: MRC - Member of College of Experts, Molecular and Cellular Medicine Board.
  • 2003 - ongoing: Caledonian Research Foundation - Biomedical Research Fellowship Committee for the RSE
  • 2001 - 2004: Wellcome Trust - Physiology & Pharmacology Panel
  • 1998 - 2004: MRC - Advisory Board
  • 1995 - 1998: MRC - PMIB "A"

Invited International Presentations

  • 2017: Barga, Italy - Molecular Pharmacology 'Gordon Conference': GPCRs - 'From Single Molecules to New Forms of Treatment'.
  • 2016: London, UK - Pharmacology 2016
  • 2016: Melbourne, Australia - ASCEPT/MPGPCR meeting, British Pharmacological Society
  • 2016: Berlin, Germany - European Pharma Summit: 3rd GPCR Targeted Screening meeting, Keynote presentation
  • 2016: Leicester, UK - BPS 6th Cell Signalling Meeting
  • 2016: University of Liege, Belgium
  • 2016: Keystone, Colorado, USA - Keystone Symposium: 'G Protein-Coupled Receptors: Structure, Signaling and Drug Discovery'.
  • 2015: Amsterdam, The Netherlands - ONCORNET initial meeting
  • 2015: Bonn, Germany - German Society for Pharmacology
  • 2015: Sweden - Astra-Zeneca
  • 2015: Milwaukee, Wisconsin - International Two-photon Microscopy Symposium
  • 2015: Glasgow, UK - International Society for Advancement of Cytometry. Keynote 'State of the Art' lecture.
  • 2015: Tartu, Estonia - European Society for Neurochemistry. 'Signal transduction models in CNS - from calculations to in vivo assay.'
  • 2015: Tokyo, Japan - 12th GPCR research meeting
  • 2015: Tokyo, Japan - Tokyo University of Agriculture and Technology
  • 2015: Berlin, Germany - 'GPCR Targeted Screening' - Keynote Speaker
  • 2015: Allschwill, Switzerland - GLISTEN GPCR meeting, Actelion Pharmaceuticals
  • 2014: Braine-L'Alleud, Belgium - SRC/KVCV Medchem 2014
  • 2014: Braine-L'Alleud, Belgium - UCB
  • 2014: Dijon, France - ECRO (European Chemoreception Research Organisation) meeting
  • 2014: Leiden, The Netherlands - GPCR Lorentz workshop 'Exploring the biology of GPCRs'
  • 2014: Mopani Lodge, Kruger National Park, South Africa - 9th Adrenoceptor/GPCR James Black Conference
  • 2014: University of Bonn, Germany
  • 2014: Leicester, UK - BPS 5th Cell Signalling Meeting
  • 2014: Berlin, Germany - Drug Discovery Innovations
  • 2014: Molndal, Sweden - Astra-Zeneca, GLAZgo Discovery Centre Inaugral meeting.
  • 2013: Aachen, Germany - Grunenthal GmbH
  • 2013: Molndal, Sweden - Astra-Zeneca, Symposium: Maximizing success in GPCRs.
  • 2013: The Netherlands - University of Utrecht Medical Centre
  • 2013: Amsterdam, The Netherlands - The 'Nauta' awards symposium
  • 2013: San Francisco, CA, USA - The Endocrine Society, Plenary Lecture: 'The year in GPCRs'.
  • 2013: San Francisco, CA, USA - The Endocrine Society, Keynote Lecture, G protein-coupled receptor forum: 'New light on GPCRs in the pathophysiology of diabetes and metabolic disorders'.
  • 2013: Paris, France - Galapagos
  • 2013: S'Agaro, Spain - Esteve Foundation Discussion Group
  • 2013: Barga, Italy - Molecular Pharmacology 'Gordon Research Conference'.
  • 2013: Boston, MA, USA - 4th GPCR Colloquium, Boston
  • 2013: Boston, MA, USA - American Society for Experimental Pharmacology and Therapeutics and British Society of Pharmacology Symposium at Experimental Biology 2013.
  • 2013: Milwaukee, Wisconsin, USA - National Science Foundation-PFI workshop 'Innovation in Two-Photon Microscopy'
  • 2013: Berlin, Germany - Drug Discovery Innovations
  • 2013: Berlin, Germany - Symposium: 'Exploring New Avenues for Small Molecule Drug Discovery'.
  • 2012: Molndal, Sweden - Astra Zeneca
  • 2012: Wurzburg, Germany - GPCR meeting
  • 2012: Bratislava, Slovakia - European Association for Animal Production (EAAP) 2012 Conference
  • 2012: Edinburgh, UK - Physiological Society Meeting, FFARmacology in diabetes – an emerging picture for the free fatty acid receptor family in disease
  • 2012: La Jolla, CA, USA - Johnson and Johnson
  • 2012: San Diego, CA, USA - American Society for Experimental Pharmacology and Therapeutics, symposium at Experimental Biology 2012
  • 2012: Paris, France - Servier
  • 2012: Berlin, Germany - 10th Annual Informa Life Sciences GPCR meeting
  • 2011: Milwaukee, USA - UW-Milwaukee Workshop on Fluorescence Microspectroscopy
  • 2011: Lunteren, The Netherlands - Dutch GPCR club
  • 2011: Washington, DC, USA - American Society for Experimental Pharmacology and Therapeutics
  • 2011: Indianapolis, IN, USA - Lilly Research Laboratories
  • 2011: Istanbul, Turkey - EHPAR symposium at Turkish Pharmacological Society meeting
  • 2011: Istanbul, Turkey - EHPAR symposium at Turkish Pharmacological Society meeting
  • 2011: Ventura, CA USA - Gordon Research Conference 'Molecular Pharmacology'
  • 2011: Indianapolis, IN, USA - Lilly Research Laboratories
  • 2011: Bonn, Germany - 'Integrated Pharmacology: Signaling from Cells to Systems'
  • 2011: Washington DC, USA - American Society for Experimental Pharmacology and Therapeutics, symposium at Experimental Biology
  • 2011: Manchester, UK - 5th ELRIG Drug Discovery meeting
  • 2011: Istanbul, Turkey - EHPAR symposium
  • 2011: Berlin, Germany - 9th Annual IIR GPCR meeting, Keynote presentation
  • 2010: Montreux Switzerland - 2nd Annual GPCRs Congress
  • 2010: Helsinki, Finland - GPCRs 2010
  • 2010: Boston, MA, USA - 2010 Pepducin Science Symposium
  • 2010: Uppsala University, Sweden - The Svedberg Lecture Series
  • 2010: Barcelona, Spain - Screening Europe 2010, 'Keynote' lecture 'What are the right assays to select?'
  • 2010: Boston, MA, USA - GPCR-based Drug Discovery: Designing and Optimizing Therapies Targeting GPCRs
  • 2010: Nottingham, UK - Systems biology of GPCR signalling' - Plenary Lecture
  • 2010: Toronto, Canada - 11th annual Great Lakes GPCR retreat, Keynote Address: The Hyman Niznik Memorial Lecture
  • 2010: Berlin, Germany - Keynote Presentation: 8th Annual 'G Protein-Coupled Receptors in Drug Discovery' meeting. 'Cutting edge developments in GPCR science and their impact on drug discovery'
  • 2009: Wuerzburg, Germany - GPCR dimerisation meeting
  • 2009: Boston, MA, USA - Keynote presentation, Cambridge Healthtech Institute 'Discovery on Target' GPCR-based drug discovery
  • 2009: Leicester, U.K. - 3rd British Pharmacological Society Focused Meeting on Cell Signalling
  • 2009: Lille, France - Society for Biomolecular Sciences, Bioassay & Technology Innovation: 15 Years of Shaping Drug Discovery
  • 2009: Lille, France - Programme Chair, GPCR Drug Discovery Symposium
  • 2009: GSK, Stevenage, UK - Biochemical Society Focused meeting 'Revolutionising Drug Discovery with Stem Cell Technology'
  • 2009: Noordwijkerhout, Holland - Programme Chair, Noordwijkerhout Camerino-Cyprus Symposium 'Trends in Drug Research'
  • 2009: Barcelona, Spain - 7th IBC/IIR Annual GPCR meeting
  • 2009: Barcelona, Spain - Chairperson of the 7th Annual Congress: G Protein-Coupled Receptors in Drug Discovery. Keynote presentation, 'Orthosteric and allosteric control of the free fatty acid receptors FFA2 and FFA3',
  • 2009: Barga, Italy - Programme Chair, 'Gordon' Conference, Molecular Pharmacology
  • 2009: Graz, Austria - Austrian Pharmacological Society, The EPHAR lecture.
  • 2009: Portland, USA - Programme Chair, 35th International Narcotics Research Conference
  • 2008: San Diego, CA, USA - American Society of Pharmacology and Experimental Therapeutics (ASPET) 100th Anniversary meeting
  • 2008: Berlin, Germany - 6th Annual G protein-coupled receptors in drug discovery
  • 2008: Federation of European Pharmacological Societies (EPHAR),
  • 2008: Barcelona, Spain - European College of Neuropsychopharmacology
  • 2007: Lisbon, Portugal - Keynote Presentation IIR GPCR meeting
  • 2007: Leiden, Holland - University of Leiden
  • 2007: Boston, MA, USA - Genzyme
  • 2007: Southampton, England - Ferring Pharmaceuticals, Symposium on G-protein coupled receptors.
  • 2007: Biddeford, Maine, USA. - Gordon Research Conference on "Phosphorylation and G Protein Mediated Signaling Networks", University of New England
  • 2007: Barcelona, Spain - Keynote Presentation, 'Novel Assay Technologies for the Discovery of GPCR Drugs", Screening Europe Conference
  • 2007: Lexington, MA, USA - EPIX Pharmaceuticals
  • 2007: Glasgow, Scotland - LifeSciences 2007
  • 2007: Prague, Czech Republic. - 6th International Conference of the Czech Neuroscience Society
  • 2007: Melbourne, Australia - Molecular pharmacology of G protein-coupled receptors
  • 2007: Leicester, England - British Society for Pharmacology, Cell Signalling meeting,
  • 2007: Ridgefield, CT, USA. - Boehringer Ingelheim
  • 2006: Las Vegas, Nevada, USA - Plenary Lecture, 11th IBC 'G protein coupled receptor meeting'.
  • 2006: Beijing, China - Speaker and Chair of the Symposium' Frontiers in G-Protein Coupled Receptor Research' - 15th International Union of Pharmacology (IUPHAR)
  • 2006: Biberach, Germany - Boehringer-Ingelheim
  • 2006: Keystone, CO, USA - Co-chair and co-organiser of Keystone Conference on G protein coupled receptors. Evolving concepts and drug discovery.
  • 2006: Glasgow, Scotland - 8th European Congress of Endocrinology,
  • 2006: La Jolla, CA, USA - Plenary Lecture - CHI Drug Discovery Chemistry, G protein coupled receptor drug discovery
  • 2006: Sarasota, FL, USA - Association for Chemoreception Sciences.
  • 2006: Istanbul, Turkey - Plenary lecture: 19th International Symposium on Medicinal Chemistry
  • 2006: Santiago de Compostela, Spain - Plenary Lecture Spanish Society of Pharmacology
  • 2006: Oss, The Netherlands - Organon plc.
  • 2006: Fort Lauderdale, FL, USA - Association for Research in Vision and Ophthalmology, 'Rhodopsin, advances and perspectives'.
  • 2006: Stockholm, Sweden - Nordic GPCR meeting 'G protein-coupled receptors-From molecular aspects to novel therapy'. Karolinska Institute, Nobel Forum
  • 2006: Lunteren, The Netherlands - Ariens Award Lecture, Dutch Pharmacological Society
  • 2006: Barcelona, Spain - Plenary Lecture at 4th IIR Annual GPCR Congress.
  • 2006: Berlin, Germany - Ernst Schering Foundation Symposium on 'G protein-coupled receptors: from deorphanisation to lead structure identification'.
  • 2006: Frankfurt, Germany - Plenary Lecture at GDCh medicinal chemistry meeting.
  • 2005: Boston, MA, USA - 'The Health of Nations'. Scotland and America-defining Life Science Partnerships. 'Tartan Day' 2005
  • 2005: Amsterdam, Holland - Plenary Lecture at 3rd Annual European Conference on G Protein Coupled Receptors in Drug Discovery
  • 2005: Washington DC, USA - PharmaDiscovery, Washington DC Convention Centre
  • 2005: Philadelphia PA, USA - Merck GPCR symposium 'GPCR dimerization: implications for pharmacology and function'
  • 2005: Leicester, UK - Plenary Lecture, BPS 'Cell Signalling meeting'
  • 2005: Washington DC Convention Centre, Washington DC, USA - PharmaDiscovery 2005
  • 2005: Hilton Waikoloa Village, Waikoloa, Hawaii, USA - 44th Annual American College of Neuropsychopharmacology meeting.
  • 2005: Bellvue, Washington State, USA - Plenary Lecture at 10th IBC G protein-coupled receptor meeting.
  • 2005: Amsterdam, Holland - 3rd Annual European Conference on G Protein Coupled Receptors in Drug Discovery
  • 2004: Kyoto, Japan. - 2nd International Pharmaceutical Sciences World Congress, 'The global translation of science into drug development in advancing therapy'
  • 2004: University of Freiberg, Germany.
  • 2004: Frankfurt, Germany. - 16th Friedrich Merz Guest Professorship Symposium. GPCRs as targets for the treatment of CNS diseases.
  • 2004: Stockholm, Sweden. - International Wenner-Gren Symposium 'Receptor-receptor interactions among heptaspanning membrane receptors: From structure to function'
  • 2004: Organon plc Newhouse, UK. - Biochemical Society 'Allosterism & GPCR accessory proteins: new insights into drug discovery'
  • 2004: Glasgow, UK. - BioScience 2004. From molecules to organisms.
  • 2004: Copenhagen, Denmark. - 18th International Symposium on Medicinal Chemistry.
  • 2004: Taos, New Mexico, USA. - Keystone Conference on G protein coupled receptors.
  • 2004: San Diego, CA, USA - Plenary Lecture, 9th IBC International G-protein coupled receptors conference
  • 2004: Genentech, San Francisco, CA, USA.
  • 2004: Amsterdam, The Netherlands. - 2nd annual IIR conference on G Protein Coupled Receptors in Drug Discovery.
  • 2004: Aventis plc, Tucson, Arizona, USA
  • 2004: American Chemical Society, Anaheim, CA, USA.
  • 2004: London, UK. - G protein coupled receptors, New approaches to maximise the impact of GPCRs in drug discovery.
  • 2004: Novasite, San Diego, CA, USA.
  • 2003: Hinxton Hall, Cambridge, UK. - Recent advances in protein kinase and G protein coupled receptor drug discovery.
  • 2003: Almirall Prodesfarma, Barcelona.
  • 2003: Free University of Amsterdam, Amsterdam, The Netherlands.
  • 2003: Prague, Czech Republic. - 16th European College of Neuropsychopharmacology
  • 2003: Cologne, Germany. - Cellular Assay Technologies GPCR's * Kinases * Ion Channels * Nuclear Receptors.
  • 2003: Boston, MA, USA. - 8th Annual IBC International Conference on 'G protein-coupled receptors'
  • 2003: Camerino, Italy. - 14th Camerino-Noordwijkerhout Symposium
  • 2003: Institute of Physiology, Czech Acamedy of Sciences, Prague, Czech Republic.
  • 2003: Perpignan, France. - International Narcotics Research Conference.
  • 2003: San Diego, CA, USA. - Experimental Biology
  • 2003: Fukui, Japan. - 4th International Symposium on receptor mechanisms.
  • 2003: Strasbourg, France. - G protein coupled receptors in Drug Discovery
  • 2003: Zurich, Switzerland. - Smart Assays for Screening
  • 2002: Aventis PLC, Frankfurt, Germany.
  • 2002: Cambridge, UK. - 1st British Pharmacological Society
  • 2002: Axaron, Heidelberg, Germany
  • 2002: San Diego, CA, USA. - 7th Annual IBC International Conference on G protein-coupled receptors.
  • 2002: Charles University, Prague, Czech Republic.
  • 2002: University of Melbourne, Melbourne, Australia. - Molecular pharmacology of G protein-coupled receptors. The Australasian Society for Clinical and Experimental Pharmacology and Toxocology.
  • 2002: S'Aguru, Spain. - Esteve Foundation meeting on "Inverse Agonism"
  • 2002: 7-TM Pharma, Copenhagen, Denmark.
  • 2002: Berlin Germany. - Assay Development: Developing successful assays and infrastructure for advanced screening in the drug discovery industry.
  • 2002: University of Hamburg, Germany.
  • 2001: Institute of Cellular Signalling, University of Nijmegen, The Netherlands.
  • 2001: Novasite Pharmaceuticals, San Diego CA, USA.
  • 2001: Scottsdale, AZ, USA - 6th Annual IBC International Conference on G protein-coupled receptors. New Insights and Drug Discoveries.
  • 2001: Department of Neuroscience, Karolinska Institute, Stockholm, Sweden.
  • 2001: Institute of Molecular and Cellular Biology, Singapore.
  • 2001: Instituto Cajal, Madrid, Spain.
  • 2001: Noordwijkerhout, Holland. - Noordwijkerhout-Camerino Symposium, "Trends in Drug Research"
  • 2001: Orlando FL, USA. - American Society for Pharmacology and Experimental Therapeutics (ASPET) symposium on
  • 2001: Vrije Universiteit, Amsterdam. The Netherlands. - The 1st NAUTA Prize Lecture.
  • 2001: Christchurch, New Zealand. - 34th International Congress of Physiological Sciences: From Molecule to Malady.
  • 2001: University of Western Australia, Perth, Australia
  • 2001: Utrecht, The Netherlands - Dutch G protein-coupled receptor symposium.
  • 2001: Western Australian Institute for Medical Research, Perth, Australia.
  • 2001: Athens, Greece. - "Demokritos"
  • 2001: Laboratory of Allergic Diseases, NIAID/NIH, Bethesda MD, USA

Prizes, Awards and Distinctions

  • 2006: Dutch Pharmacological Society 'Ariens' Prize
  • 2001: First Nauta Visiting Professor to the Vrije Universiteit Amsterdam
  • 1998: Poulsson Medal for Pharmacology, Norwegian Society of Pharmacology & Toxicology

Professional Learned Society

  • 1998 - ongoing: Royal Society of Edinburgh - Fellow

Publications

List by: Type | Date